Targeting a protein involved in aggressive B-cell lymphoma
Official title: Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma
Funded at Ohio State University · NIH-11042777 · Data updated 2026-11-12
This study is looking at a type of aggressive lymphoma called double and triple-hit lymphomas to understand how a protein named TBL1X affects the disease, with the goal of finding better treatments to help patients live longer and healthier lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | April 1, 2022 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $570,593 |
| NIH project number | 5R01CA266682-04 |
| Project ID | NIH-11042777 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with double or triple-hit B-cell lymphomas who have high levels of c-Myc and BCL2 protein expression.
✕Less likely to help
Patients with other types of lymphomas or those without the specific protein overexpression may not benefit from this research.
What this research studies
This research focuses on a specific type of aggressive B-cell lymphoma known as double and triple-hit lymphomas, which are characterized by the overexpression of certain proteins that lead to poor patient outcomes. The study aims to investigate the role of a protein called TBL1X in these lymphomas and explore new therapeutic strategies to improve survival rates. By understanding how TBL1X contributes to the disease, researchers hope to develop targeted treatments that could be more effective for patients with this challenging condition.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatments for patients with aggressive B-cell lymphomas, potentially improving survival rates.
How similar studies have gone: Other research has shown promising results in targeting similar pathways in aggressive lymphomas, suggesting that this approach may be effective.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Alinari, Lapo — Ohio State University
- Study coordinator: Alinari, Lapo
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.